Percheron Therapeutics (ASX:PER) advanced its phase 2b trial investigating the use of avicursen (ATL1102) in patients with Duchenne muscular dystrophy, according to a Monday filing with the Australian bourse.

All 48 patients from the randomized, placebo-controlled trial completed their 25th-week visit, with results expected by the week starting Dec. 16, the filing said. The trial's 12-month study data is anticipated for mid-2025.

The company's shares were down almost 3% in recent Monday trade.

Price (AUD): $0.07, Change: $-0.002, Percent Change: -2.70%